Trade between Mozambique and South Africa reaches over two billion dollars annually - AIM report
FNM presents success story of medicine production in Mozambique
4:25 CAT | 31 Jul 2025
Photo courtesy: Fábrica Nacional de Medicamentos (FNM)
The National Medicines Factory (FNM) presents its success story in medicine production in Mozambique as part of the Mozambique International Health Expo and Summit 2025 (MIH EXPO 2025), held in Maputo from July 30 to 31 of this year.
.The presentation took place on July 31 at 1:00 pm in Panel 7, which was themed “Local Production: Investment in the Local Pharmaceutical Industry – Success Stories.”
The FNM has been undertaking bold initiatives to increase production capacity and ensure quality assurance, in response to the efforts of the Government of Mozambique, which, in this new governance cycle, is strongly committed to promoting local medicine production, aiming to replace imports and ensure the full supply of the National Health Service with quality and affordable medicines.
In 2024, FNM was proudly awarded the WHO – World Health Organization Prequalification Certificate for pharmaceutical production. With this certification, FNM positions itself as a company with the highest quality standards in pharmaceutical production, qualifying it to market its products both domestically and internationally. With this WHO Prequalification, FNM is expanding its production capabilities and positioning itself as a leading producer in Africa.
In 2020, FNM established a partnership with the Mozambican State that enabled the establishment of INFARMA – Pharmaceutical Industry, a subsidiary that increased domestic production capacity. Both factories have state-of-the-art industrial facilities and state-of-the-art equipment, ready to meet local and international demand. Both are certified in Good Manufacturing Practices (GMP), an essential requirement that demonstrates a robust quality management system.
The two factories have been producing essential, global-class pharmaceuticals for approximately 10 years, already covering approximately 50% of the national health service’s consumption and contributing to various therapeutic solutions, including antihypertensives, antibiotics, anticonvulsants, antihistamines, antidiabetics, antifungals, analgesics, antibacterials, antacids, antidiarrheals, vitamins, antimalarials, and antiretrovirals.
With the creation of INFARMA, FNM took a giant step toward increasing and diversifying pharmaceutical production in Mozambique. In addition to training staff and increasing production capacity at the oral solids (tablets and capsules) factory, – a unit previously owned by the Mozambican Society of Medicines – two new factories were subsequently developed for the production of large-volume injectables and vaccines. These new projects will contribute to increasing Mozambique’s health sovereignty.
The start of injectable and vaccine production will be a very important milestone for our country, as it will allow for the complete replacement of imports of large-volume injectables (serums) and partial replacement of vaccines, as well as the establishment of Mozambique in the international arena as a country with high-tech industries.
FNM and its subsidiary INFARMA jointly offer a production capacity of more than 2 billion tablets, capsules, and powder suspensions, more than 18 million large-volume injectable bags, and more than 50 million doses of vaccines in more than 100 drug formulations. 9. Together, these factories produce the following types of medications:
- Multiple oral solids (tablets, capsules, and powder suspensions)
- Antiretrovirals
- Penicillin antibiotics
- Large-volume injectables (installation is nearing completion)
- Vaccines (installation is nearing completion)
To ensure the expansion of the pharmaceutical portfolio, with more new-generation, cutting-edge drugs, the national factories have partnered with renowned global manufacturers, such as VIATRIS, a global pharmaceutical company, through the implementation of cooperation and technology transfer projects.
Source: Fábrica Nacional de Medicamentos (FNM) / Media Release
Show comments
Also read
Leave a Reply
Be the First to Comment!
You must be logged in to post a comment.
You must be logged in to post a comment.